What differentiates an FDA Section 361 tissue allograft from a Section 351 biological product?

Section 361 human cellular and tissue-based products (HCT/Ps) are regulated strictly to prevent infectious disease transmission and must meet criteria including minimal manipulation, homologous use, and non-systemic biological action. Section 351 products involve more than minimal manipulation, non-homologous applications, or reliance on living cell metabolic activity for primary function, requiring formal FDA clinical trials and pre-market approval (BLA).

What compliance documentation must a practice manager collect from an allograft supplier?

Practice administrators should verify the supplier's FDA Establishment Registration number (FEI), request lot-specific Certificates of Analysis (CoA), and review donor screening protocols conducted in CLIA-certified laboratories. Furthermore, practices must maintain traceable chain-of-custody documentation, including thermal packing logs and receiving verification forms for every shipment.

Can Section 361 tissue allografts be marketed or used for systemic anti-aging therapies?

No. Under FDA regulations, Section 361 tissue allografts cannot be marketed or clinically applied for systemic metabolic effects, anti-aging, or organ-system treatments. They must be utilized strictly for local structural support or repair in applications that match the tissue's original anatomical function.

How should cryogenic tissue allografts be handled and logged within clinical practice workflows?

Cryogenic tissue products must be transferred immediately upon delivery into calibrated ultralow freezers or liquid nitrogen storage units with continuous temperature monitoring. Clinical teams must document the donor lot number, expiration date, receiving temperature, patient identification, and internal dispensing clinician for strict regulatory compliance.

Does holding an FDA Establishment Registration mean an allograft product is FDA approved?

No. FDA Establishment Registration is an administrative requirement indicating that a facility processes or distributes HCT/Ps under 21 CFR Part 1271; it does not constitute FDA evaluation, clinical approval, or endorsement of specific tissue products. Practice managers should avoid distributors that claim their Section 361 allografts are 'FDA approved.'

Practice Operations · For practice managers

FDA Section 361 Compliant Tissue Allograft Sourcing Guide

Published October 3, 2026

Regulatory Classification Standard: 21 CFR Part 1271 Section 361
Core Compliance Standard: cGTP & AATB Accreditation Alignment
Operational Protocol Focus: Strict Thermal & Chain-of-Custody Tracking

FDA Section 361 compliant tissue allograft sourcing for medical practices requires verifying that human cellular and tissue-based products (HCT/Ps) satisfy 21 CFR Part 1271 regulatory standards, including minimal manipulation and homologous use. Establishing compliant procurement protocols protects clinical practices from regulatory enforcement while ensuring rigorous donor screening, standard tissue processing, and transparent chain-of-custody tracking. Establishing relationships with reputable tissue distributors allows practice managers and medical directors to integrate high-integrity structural allografts into patient care plans seamlessly.

Understanding the FDA Section 361 Regulatory Framework

Navigating the regulatory landscape for human cellular and tissue-based products requires clear differentiation between FDA Section 361 and Section 351 pathways under 21 CFR Part 1271. For medical practices offering regenerative structural solutions, procuring products that adhere to Section 361 guidelines is fundamental to maintaining legal compliance and patient safety.

To qualify as a Section 361 tissue product, an HCT/P must meet four core criteria established by the FDA:

Minimal Manipulation: The processing of the tissue does not alter its original relevant biological characteristics or structural utility.
Homologous Use: The tissue is intended to perform the same basic function in the recipient as it performed in the donor (e.g., providing structural cushioning, barrier coverage, or focal tissue repair).
No Combination: The tissue is not combined with another drug, device, or non-tissue agent, except for approved preservation agents.
Non-Systemic Action: The tissue does not rely on the metabolic activity of living cells for its primary function, or, if it does, it is intended strictly for autologous use, allogeneic use in first- or second-degree blood relatives, or reproductive use.

Products that fall outside these criteria—such as tissues subjected to extensive chemical processing, those marketed for systemic biological effects, or those combined with active pharmaceutical agents—are classified as Section 351 drugs or biologics. Section 351 products require extensive pre-market clinical trials, Investigational New Drug (IND) applications, and Biologics License Applications (BLA). Practice administrators must carefully audit supplier documentation to confirm that all procured biologics fit firmly within Section 361 limits.

Operational Sourcing Checklist: Vetting Vendor Compliance

Practice managers bear the responsibility of safeguarding practice operations against regulatory vulnerability and supply chain disruptions. Establishing a systematic procurement checklist ensures that every tissue allograft introduced into the clinical environment meets strict quality and legal benchmarks.

Essential Vendor Verification Steps

Verify FDA Establishment Registration: Ensure the manufacturing facility and distributor maintain active registration on the FDA Establishment Identifier (FEI) database under 21 CFR Part 1271.
Inspect Current Good Tissue Practice (cGTP) Standards: Confirm that tissue recovery, processing, storage, and distribution adhere to cGTP regulations, preferably supported by American Association of Tissue Banks (AATB) accreditation.
Audit Donor Eligibility Documentation: Review donor testing criteria to ensure screening covers required infectious disease markers (including HIV, Hepatitis B, Hepatitis C, Syphilis, and HTLV) executed by CLIA-certified laboratories.
Confirm Homologous Use Declarations: Ensure the manufacturer’s technical literature, package inserts, and promotional claims strictly reflect structural, homologous applications without making non-compliant systemic treatment claims.
Evaluate Cold-Chain and Storage Integrity: Review supplier shipping protocols. Cryogenic and refrigerated products must ship with calibrated thermal indicators and validated packaging to ensure thermal integrity throughout transport.
Review Lot Traceability Systems: Verify that each allograft unit includes unambiguous lot numbers, expiration dates, and donor tracking identifiers to facilitate seamless internal inventory management.

Clinical Considerations: Matching Allograft Selection to Patient Needs

From a clinical perspective, selecting the appropriate tissue matrix depends on the structural needs of the target tissue site and the patient's individual clinical profile. Physicians specializing in orthopedic care and pain management require tissue options that provide robust extracellular structural architecture, high tensile strength, and protective barrier functions.

Structural Properties of Common Section 361 Allografts

Wharton's Jelly & Umbilical Cord Matrix: Rich in structural proteins, extracellular matrix components (such as collagen types I, III, and IV), and high concentrations of hyaluronic acid. Used clinically to provide local structural support, mechanical cushioning, and micro-environmental architecture in damaged musculoskeletal structures.
Amniotic Membrane Allografts: Provide dual-layer structural barriers that exhibit low immunogenicity and physical protective qualities. Frequently utilized to reduce surgical adhesion formation, serve as biological wound covers, or protect sensitive nerve structures during repair.
Acellular Dermal & Cartilage Matrices: Processed to remove cellular debris while preserving the structural collagenous lattice, offering a scaffold for host tissue repair and structural augmentation.

Clinicians must ensure that the mechanical properties of the selected matrix align with the physical demands of the anatomical site. For instance, focal joint defects require load-bearing structural cushioning, whereas superficial soft tissue repair prioritizes flexible barrier coverage and structural matrix integrity.

Cost Structure and Workflow Optimization for Procurement Managers

Integrating tissue allografts into practice procurement workflows requires balancing upfront acquisition costs, inventory holding requirements, and administrative efficiency. Practice administrators must design operational protocols that minimize waste, streamline receiving procedures, and maintain flawless clinical record-keeping.

Inventory Management and Capital Allocation

Storage requirements represent a primary operational consideration. Tissue allografts typically require specific thermal control environments:

Cryogenic Storage (-80°C to -196°C): Requires dedicated ultralow temperature freezers or liquid nitrogen dewars equipped with independent thermal monitoring and alarm systems. Ideal for practices with high procedural volume that can justify infrastructure capital.
Ambient/Dehydrated Storage (15°C to 30°C): Room-temperature allografts eliminate the capital expense of specialized freezers and lower transport costs, making them advantageous for smaller clinics or lower-volume specialty practices.

To optimize inventory efficiency, practice managers should implement a First-In, First-Out (FIFO) stock rotation system tied directly to your electronic health records (EHR) or inventory management software. Documenting receiving temperatures, lot numbers, and expiration dates immediately upon arrival prevents inventory loss due to thermal compromise or inadvertent stock expiration.

Administrative and Reimbursement Compliance

Because Section 361 tissue allografts utilized in cash-pay or hybrid practice models are often billed as unclassified structural supplies or bundled into procedural fees, financial transparency is essential. Practice administrators should establish standardized fee schedules that account for product unit cost, shipping, storage overhead, and clinical handling fees. Maintaining precise logbooks linking every allograft lot number to the specific patient record ensures defensible audit trails in the event of administrative review.

What This Means for Your Practice

To ensure your facility's procurement framework is safe, effective, and fully compliant, take these concrete operational steps:

Conduct an Immediate Vendor Audit: Review all active tissue vendors to verify FDA registration, cGTP compliance documentation, and strict adherence to homologous use marketing guidelines.
Establish Cold-Chain Intake SOPs: Train intake personnel to inspect thermal indicators, record shipment arrival temperatures, and immediately log lot numbers into your inventory system before clinical storage.
Align Clinical Application Protocols: Work with medical staff to ensure that clinical notes explicitly document structural, homologous rationale for tissue application in alignment with regulatory definitions.
Standardize Patient Consent Forms: Update procedural consent forms to clearly detail the origin, structural purpose, and tissue processing background of allogeneic tissue matrices.

Reviewing regulatory criteria and administrative requirements on our FAQ page can help practice managers build robust operational protocols.

Partner with Dallas Regenerative Solutions

Navigating tissue procurement requires a trusted distribution partner dedicated to regulatory transparency, product quality, and operational support. Dallas Regenerative Solutions supplies licensed practices with fully compliant, high-integrity Section 361 tissue allografts and advanced regenerative technologies designed to elevate clinical outcomes and streamline practice management.

Contact Dallas Regenerative Solutions today to schedule a consultation with our practice integration specialists and evaluate compliant tissue options tailored to your specialty.

Frequently asked questions

What differentiates an FDA Section 361 tissue allograft from a Section 351 biological product?: Section 361 human cellular and tissue-based products (HCT/Ps) are regulated strictly to prevent infectious disease transmission and must meet criteria including minimal manipulation, homologous use, and non-systemic biological action. Section 351 products involve more than minimal manipulation, non-homologous applications, or reliance on living cell metabolic activity for primary function, requiring formal FDA clinical trials and pre-market approval (BLA).
What compliance documentation must a practice manager collect from an allograft supplier?: Practice administrators should verify the supplier's FDA Establishment Registration number (FEI), request lot-specific Certificates of Analysis (CoA), and review donor screening protocols conducted in CLIA-certified laboratories. Furthermore, practices must maintain traceable chain-of-custody documentation, including thermal packing logs and receiving verification forms for every shipment.
Can Section 361 tissue allografts be marketed or used for systemic anti-aging therapies?: No. Under FDA regulations, Section 361 tissue allografts cannot be marketed or clinically applied for systemic metabolic effects, anti-aging, or organ-system treatments. They must be utilized strictly for local structural support or repair in applications that match the tissue's original anatomical function.
How should cryogenic tissue allografts be handled and logged within clinical practice workflows?: Cryogenic tissue products must be transferred immediately upon delivery into calibrated ultralow freezers or liquid nitrogen storage units with continuous temperature monitoring. Clinical teams must document the donor lot number, expiration date, receiving temperature, patient identification, and internal dispensing clinician for strict regulatory compliance.
Does holding an FDA Establishment Registration mean an allograft product is FDA approved?: No. FDA Establishment Registration is an administrative requirement indicating that a facility processes or distributes HCT/Ps under 21 CFR Part 1271; it does not constitute FDA evaluation, clinical approval, or endorsement of specific tissue products. Practice managers should avoid distributors that claim their Section 361 allografts are 'FDA approved.'

Continue reading

FDA Compliant Tissue Allograft Vendor Vetting Checklist
A comprehensive checklist for physicians and practice managers evaluating tissue allograft vendors, focusing on FDA compliance, tissue safety, cold-chain integrity, and liability protection.
How to Vet Regenerative Biologic Suppliers for Compliance
A comprehensive guide for practice managers and medical directors on evaluating regenerative biologic vendors for regulatory compliance, safety protocols, and risk mitigation.
Vetting Biologic Suppliers for Tissue Safety
A comprehensive guide for practice managers and clinicians on vetting tissue suppliers, verifying cGTP compliance, and mitigating regulatory risk.
Vet Biologic Suppliers for FDA Compliance & Safety
A step-by-step guide for practice managers and administrators evaluating regenerative biologic vendors for regulatory compliance, tissue safety, and operational integration.